Oncolinc Therapeutics Inc.

Oncolinc Therapeutics is a pharmaceutical company pioneering a first-in-class approach to overcome immune resistance in cancer and improve patient survival. Oncolinc’s lead therapeutic silences a recently discovered long non-coding RNA (lncRNA) molecule that enables cancer cells to hide from the immune system. By silencing this lncRNA, the therapy restores immune recognition and has the potential to unlock treatment responses across major solid tumors, including breast, lung, colon and brain. Their proprietary discovery pipeline expands this strategy beyond a single target and can be used alone or in combination with existing immunotherapies to help an estimated 50% of all cancer patients benefit from treatment.